Advicenne extends its cash reserves until 2028

Advicenne, a pharmaceutical company specializing in nephrology and neurology, has strengthened its cash position until 2028. This extension is the result of strict management and strong commercial performance, particularly thanks to the drugs Likozam®, Levidcen®, and Sibnayal®. The receipt of €1 million from a bond financing agreement signed with L1 Capital significantly contributed to this improvement. Previously, financial visibility was projected only until the second quarter of 2027. The company also highlights the possibility of additional financing of €1.2 million from its partners and management.